atai Life Sciences’ EmpathBio announces joint feasibility assessment of Bionomics’ BNC210 and EmpathBio’s MDMA derivative EMP-01 treatment regimen for PTSD

February 17, 2021 Articles 11:31 am

Bionomics Limited today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences. Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics’ BNC210 and EmpathBio’s 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01. The parties will explore whether the different mechanisms of action of EMP-01 and BNC210 may offer the potential for developing an improved treatment regimen for the treatment of Post-Traumatic Stress Disorder (PTSD).


Receive the latest news on atai and innovations in the space.